COPD and Inflammatory Mediators

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-31

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease (COPD) is widely spread all over the world. It is predicted to be the third leading cause of death by 2020.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exercise Training and Inflammatory Mediators in COPD

NCT03853174

COPD

COMPLETED NA

Chronic Obstructive Pulmonary Disease

NCT03577080

COPD

COMPLETED NA

Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease

NCT06956742

Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING NA

The Effect of Two Weeks of Voluntary Reduced Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)

NCT02221804

Chronic Obstructive Pulmonary Disease (COPD) Muscle Atrophy

UNKNOWN NA

Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

NCT03551197

Pulmonary Disease, Chronic Obstructive Exercise Lung Function Decreased +1 more

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

COPD is a common, preventable treatable disease that is characterized by an airflow limitation which is not fully reversible.Not only the long-term exposition to noxious particles and gases contributes to the development of COPD, but also many others factors such as genetics and cigarette smoking. Cigarettes are harmful and contribute to different extra pulmonary disorders. Although COPD affects lungs some extrapulmonary manifestations are prescribed such as muscle dysfunction, abnormal respiratory muscles and systemic inflammation. Indeed, the systemic inflammation\[6, 8\] is considered as a key process in the pathogenesis of COPD. It involves different cells and molecules; high levels of circulating of white blood cells, increased plasma c-reactive proteins (CRP), interleukin 6 (Il6) have been reported in.those patients.Likewise, systemic inflammation could worsen the comorbidities (cardiovascular, osteoporosis..) and may lead to the exercise limitation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PR

Group Type ACTIVE_COMPARATOR

exercise training

Intervention Type OTHER

The patients are allocated to PR+ET group or PR Each group receive an exercise training

PR+ET

Group Type EXPERIMENTAL

exercise training

Intervention Type OTHER

The patients are allocated to PR+ET group or PR Each group receive an exercise training

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

exercise training

The patients are allocated to PR+ET group or PR Each group receive an exercise training

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD diagnosed by pulmonary function testing
* Clinically stable
* Abscence of other obstructive diseases
* Signed written consent

Exclusion Criteria

* Neuromuscular diseases -Severe psychiatric, neurologic or musculoskeletal conditions
* cardiovascular diseases.
* Contre-indications to physical therapy
* Acute exacerbations a month before the intervention

Minimum Eligible Age

50 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No